Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced a new clinic licensing model that would allow independent practitioners to own and operate their own clinic under the company’s brand.
On Tuesday, the psychedelic-focused company announced the new model Numinus Network where partners of Numinus will be able to run their clinics independently and benefit from Numinus’ established clinic model, training curriculum and brand. Patients would also get access to its network of healthcare professionals.
The costs and licensing fees for clinics will be determined based on various factors, such as location, regional exclusivity terms and specific licensing arrangements. As the company launches its Numinus Network, the company will also explore options for expanding its corporately-owned clinics.
“We believe that we are on the verge of a significant shift in mental health care as psychedelic-assisted therapy is becoming more accessible, and Numinus wants to take a leading role in providing this important clinical care,” CEO Payton Nyquest said in a statement.
The Numinus Network will allow us to work with practitioners who believe in the Numinus brand and protocols, but prefer greater independence in leading their team and practice,” he added.
Licensees can lease a fully operational Numinus Wellness clinic location
Numinus has formed a new partnership with Healing Commercial Real Estate Inc., a real estate investment firm that specializes in the healthcare sector and has extensive knowledge of the psychedelic industry.
As part of this collaboration, Numinus will be able to offer opportunities to lease a fully operational Numinus Wellness clinic location, complete with leasehold improvements and clinic infrastructure, directly from Healing CREI.
“This partnership presents an opportunity for Numinus to further solidify its position as one of the industry leaders prepared to meet the growing demand for psychedelic-assisted therapy services,” Healing CREI Founder Cody Shandraw said.
“Leveraging market data, we can help build clinic infrastructure using a targeted planning process to determine key regions where the psychedelic, behavioural health, and wellness industry is currently lacking or underserved,” he added.
Numinus owns clinics that focus on providing psychedelic-assisted therapy in North America using psilocybin and ketamine.
Company stock stayed flat on Tuesday at $0.22 on the Toronto Stock Exchange.